Covid-19 Aşıları

Covid-19 pandemisi 1 yılı aşkın bir süredir devam etmektedir. Alınan çeşitli önlemlere karşın pandemi sonlandırılamamıştır. Bu nedenle aşı çalışmaları önem kazanmıştır. Bazı aşıların etkinliklerinin yüksek olmasına rağmen çalışmalar hala devam etmektedir.

Anahtar Kelimeler:

Covid-19, Aşılar, Spike proteini

Covid-19 Vaccines

The Covid-19 pandemic has been going on for over one year. Despite the various measures taken, the pandemic could not be ended. Therefore, vaccination studies have gained importance. Despite the high efficacy of some vaccines, studies are ongoing.

Keywords:

Covid-19, Vaccines, Spike protein,

PDF

___

WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/table
Ball P. What the lightning-fast quest for Covid vaccines means for other diseases. Nature 2021; 16-18.
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
Krammer F. SARS-CoV-2 vaccines in development. Nature 2020; 516-27.
Callaway E. The race for coronavirus vaccines. Nature 2020; 580:576-7.
Polack FP, Thomas SJ, Kitchin N, Ablason J, Gurtman A, Lockhart S et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603-15.
World Health Organization Technical document. Background document on the mRNA vaccine BNT162b2 (Pfizer/BioNTech) against Covid-19. 14 January 2021. https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19
Shimabukoro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first döşe of Pfizer-BioNTech COVID-19 Vaccine.JAMA 2021; 325:780-1.
Baden LR, El Sahyl HM, Essink B, Kotloff K, Frey S, Novak R et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2020; Dec 30:NEJMoa2035389. Published online2020 Dec 30 doi: 10.1056/NEJMoa2035389
Morbidity and Mortality Weekly Report. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna Covid-19 vaccine-United States, December 21,2020 January 20, 2021.
WHO interim guidance. Interim recommendations for use of the Moderna mRNA-1273 vaccine against Covid-19. 25 January 2021.
Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD 1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK. Lancet 2021; 397:99-111.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS et al. Safety and immunogenicity of an rAd26 and rAd5 vector based heterologous prime-boost Covid-19 vaccine in two formulations: two open, non-randomised phase 1/2studies from Russia. Lancet 2020; 396:887-897.
Logunov DY, Dolzhikova IV, Shcheblyakov D, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS et al. Safety and immunogenicity of an rAd26 and rAd5 vector based heterologous prime-boost Covid-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397:671-81.
Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021 Jan 13: NEJMoa2034201. Published online 2021 Jan 13. doi: 10.1056/NEJMoa2034201.
https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic
Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healty adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase ½ clinical trial. Lancet Infect Dis 2021; 181-92.
Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healty adults aged 60 years and older: a randomised, double-blind, plasebo-controlled, phase ½ clinical trial. Lancet Infect Dis 2021 Feb 3 doi: 10.1016/S1473-3099(20)30987-7.
https://covid19asi.saglik.gov.tr/TR-77693/covid-19-asisi.html
Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ 2021; 372n296.
https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3